Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Webinars / 2024 / Evaluation of the Oncomine
Thermo Fisher Scientific

Evaluation of the Oncomine™️ Comprehensive Assay Plus for genomic profiling including HRD assessment

Evaluation of the Oncomine Comprehensive Assay Plus for comprehensive genomic profiling including homologous recombination deficiency assessment.

12/10/2024

Sponsored By

Share

Watch On Demand Now

December 10, 2024 - 5:00 PM CET

Evaluation of the Oncomine Comprehensive Assay Plus for comprehensive genomic profiling including homologous recombination deficiency assessment.

Precision oncology research continues to explore the utility of targeted therapies and immunotherapies. As we gain a deeper understanding of the molecular mechanisms of tumor biology, comprehensive genomic profiling (CGP) is critical to help drive insights into advancing the future of personalized medicine. In this webinar, learn how the Ion Torrent™ Oncomine™ Comprehensive Assay Plus, an amplicon-based next-generation sequencing (NGS) assay, can be used to simultaneously analyze a broad range of biomarkers, including homologous recombination deficiency (HRD), in one test to maximize insights into the underlying oncogenic drivers in timely manner.

Webinar Learning Objectives

  1. Factors to consider when evaluating NGS technologies for CGP

  2. The relevance of CGP to detect variants across tumor sample types

  3. The importance of genomic signatures like HRD testing in ovarian cancer research samples and how it can be measured

For Research Use Only. Not for use in diagnostic procedures.

 © 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

More Webinars

December 9, 2024

State of the Nation: Interrogating the Benefits and Obstacles to Digitization and AI Adoption

October 28, 2024

Optimizing Cancer Care through Strategic Selection of NGS Testing Platforms: Balancing Panel Size with DNA Input Challenges

Subspecialties Omics Oncology Precision medicine

August 28, 2024

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results

False

Advertisement

Recommended

False

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.